Liver fibrosis is caused by the continuous activation of hepatic stellate cells and the deposition of collagen in the liver after liver injury caused by various diseases such as hepatitis B, hepatitis C, autoimmune liver, alcoholic fatty liver and metabolic related fatty liver. It may progress to cirrhosis and liver cancer. Small molecule drugs and antibody drugs designed by foreign pharmaceutical companies using GalNAC as delivery tools and targeting Caspase, LOXL-2, cyclophils, Galectin-3, etc., have been promoted to clinical trials, but have not yet been marketed. However, GalNAC is a targeted drug delivery tool for hepatocytes and cannot deliver drugs to activated hepatic stellate cells, indicating that the therapeutic strategy is biased. At present, no specific targets have been found on the cell membrane of activated hepatic stellate cells. There is no effective drug to therapy liver cirrhosis.
For activated hepatic stellate cells, Beroni Group has developed Aptamer-Wu and APT-Tan nucleic acid aptamers with targeted drug delivery function through SELEX technology, avoiding the reality of no specific targets, and has obtained four national invention patents (ZL 2022 1 0892095.7; ZL 2022 1 1182426.4; ZL 2022 1 0893829.3; ZL 2022 1 1182396.7), mastering the key to targeted drug treatment of liver fibrosis and cirrhosis. At present, based on these two targeted drug delivery tools, Beroni’s research team is developing Aptamer-Wu and APT-Tan coupled nucleic acid targeted drugs for the development genes of liver fibrosis and cirrhosis, bringing good news to patients with liver fibrosis and cirrhosis! This research marks an important breakthrough in the development of innovative anti-liver cirrhosis gene therapies for Beroni Group, which will provide new treatment options and hope for patients with liver cirrhosis.
